Together, cancer meets its match
Omico is changing the way we fight cancer by accelerating access to precision oncology. We are a national, independent, not-for-profit organisation, uniting Australia’s world-class cancer institutes, researchers, clinicians, industry partners and government like never before. By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we’re accelerating access to next generation treatments and preventive strategies.
What we do
We aim to improve outcomes for Australians living with cancers, by:
- Increasing access to genomic profiling to detect unique genetic variations in cancer patients’ tumours to identify potential matches to new targeted treatments options
- Growing and streamlining biomarker-led clinical trials by expediting patient recruitment and site setup, and attracting more international trials to Australia, facilitating faster transitions from discovery to clinical application
- Advancing a research-led model of care as to open new treatment pathways for patients, and supporting drug development and cancer research through the collection of real-world data
How our molecular screening works
If you or someone you know has advanced, incurable or an earlier diagnosis of a poor prognosis cancer or is at high-risk for cancer (due to hereditary conditions) then:
- Your doctor completes an online referral form
- You sign a consent form
- Omico assesses the genes and other molecules in your cancer tissue
- Our experts match results to an existing therapy or clinical trial of a new drug
- Process takes 8 to 10 weeks
Researchers
Meet intellectually-stimulating research that changes cancer care and transforms lives.
Clinicians
Meet accelerated access to innovative new therapies for your patients.
Government
Meet an opportunity to advance the nation’s health and wealth.
Advocacy Groups
Meet a partner that can help you make a real difference for those affected by cancer.
Who we work with
Recent news
Federal Government commits $71M to life-extending precision oncology
Sydney Australia – 12 May 2026 – $71 million Federal Government investment will support Omico’s national precision oncology program PrOSPeCT 2.0*, until 2028/29.
New JAMA Oncology study shows improved survival through Omico’s MoST precision oncology program
Sydney, Australia - 5 March 2026 - A new peer-reviewed study published in JAMA Oncology shows that patients with advanced cancers lived significantly longer when their treatment was matched to genomic biomarkers using strong clinical trial evidence — highlighting how precision oncology can deliver real benefit for patients.
Omico launches a new landmark report
Sydney, Australia – 25 November 2025 - A new landmark report launched today by Omico, confirms precision oncology – the use of genomics to match a person’s tumour DNA to advanced treatments – not only extends the lives of those with incurable cancers, but simultaneously is also creating jobs and fuelling Australia’s economy. Yet without urgent action, many facing a very tough cancer diagnosis will continue to miss out.